Ultrasound-guided versus blind subacromial—subdeltoid bursa injection in adults with shoulder pain: A systematic review and meta-analysis

Tao Wu, MD*, Hai Xin Song, MD, Yan Dong, MD, Jian Hua Li, MD

Department of Rehabilitation Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, 3, East Qin Chun Road, Hangzhou, Zhe Jiang, 310016, China

ABSTRACT

Objective: This systematic review and meta-analysis aimed to assess the effectiveness of ultrasound-guided (USG) versus blind (landmark-guided, LMG) corticosteroid subacromial—subdeltoid bursa injection in adults with shoulder pain.

Methods: The searches were performed on PubMed, Ovid MEDLINE, Ovid EMBASE, Ovid CochraneCENTRAL, Web of Science, Google Scholar, and Scopus from database inception through March 27, 2015. Studies were included trials comparing USG versus LSG injections for the treatment of adults with subacromial-subdeltoid bursitis. Two reviewers independently performed data extraction and appraisal of the studies. The outcome measures collected were the decreased VAS and SDQ scores, the increased shoulder function scores and shoulder abduction motion range, and the effective rate at 6 weeks after injection.

Results: Seven papers including 445 patients were reviewed; 224 received LMG injections and 221 received USG injections. There was a statistically significant difference in favor of USG for pain score \[MD = 1.19, 95\% CI (0.39, 1.98), P = 0.003\] and SDQ score \[MD = 5.01, 95\% CI (1.82, 8.19), P = 0.02\] at 6 weeks after injection. Also there was a statistically significant difference between the groups, with greater improvement reported of shoulder function scores \[SMD = 0.89, 95\% CI (0.56, 1.23), P < 0.001\] and shoulder abduction motion range \[MD 32.69, 95\% CI (14.82, 50.56), P < 0.001\] in the USG group. More effective rate was also reported with USG group and the difference was statistically significant \[risk ratio = 1.6, 95\% CI (1.02, 2.50), P = 0.04\].

Conclusions: Ultrasound-guided corticosteroid injections potentially offer a significantly greater clinical improvement over blind SASD bursitis injections in adults with shoulder pain.

© 2015 Published by Elsevier Inc.
for shoulder pain patients. This systematic review and meta-analysis aimed to assess the effectiveness of ultrasound-guided versus blind (landmark-guided) corticosteroid SASD bursa injection in adults with shoulder pain. Outcome measures for effectiveness included change in pain and function scores. It was the hypothesis of this study that the ultrasound-guided (USG) SASD bursa injection is more effective in clinical outcomes than landmark-guided (LMG) technique in patients with shoulder pain.

Methods

This systematic review of randomized controlled trials was performed according to the current recommendations of the Cochrane Collaboration [11] and reported using the criteria of the PRISMA statement [12].

Search strategy

The searches were performed on PubMed, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane CENTRAL, Web of Science, Google Scholar, and Scopus from database inception through March 27, 2015. Key search terms were blind, landmark, anatomical, image-guided, ultrasound, fluoroscopy, steroid injection, subacromial—subdeltoid bursa, subacromial, random allocation, randomized controlled trial (RCT), and clinical trial. Each concept used a combination of controlled vocabulary (MeSH and EMTREE) combined with text words for each database that uses subject heading (PubMed, MEDLINE, EMBASE, CENTRAL). Web of Science and Scopus depend primarily on text words alone.

Inclusion and exclusion criteria

We included randomized controlled trials (RCTs) comparing the clinical effectiveness of USG and LMG SASD bursa or subacromial injection in shoulder pain patients. Anatomical target locations include SASD bursa or subacromial space. Outcomes of interest included pain, function, range of motion, and proportion of participants with overall improvement. Exclusion criteria were case reports, technical reports, pilot and uncompleted studies, studies with no data analysis and/or power analysis, and acromioclavicular or glenohumeral injection.

Study selection

Once all relevant full-text papers had been gathered, the reference lists of each eligible paper were scrutinized by two reviewers (Y.D. and T.W.) for any omitted studies. Each search was imported into an EndNote (Thomson Reuters Research Soft), a bibliographic database manager, and duplicates were removed. All conflicts were discussed and resolved with a third author (J.H.). The reference sections of all articles were used to identify additional relevant articles.

Data collection process and outcome measures

Following selection of all relevant articles, two authors (Y.D. and T.W.) extracted all data into a pre-constructed data table. The following data was extracted: author, year published, study location, sample size, patient characteristics (gender and age), injection approach, follow-up period, and outcomes. The outcome measures collected were the decreased VAS and SDQ scores, the increased shoulder function scores and shoulder abduction motion range, and the effective rate at 6 weeks after injection. Shoulder functional outcome measurements used instruments such as SFA score [13], constant score [14], and physical function [15].

Statistical analysis

All analyses were performed using the generic inverse variance method (Rev Man 5.3, The Cochrane Library). Statistical heterogeneity was quantified using the *I²* statistic and the chi-square-based test. The decreased VAS and SDQ scores, increased shoulder function scores, and shoulder abduction motion range at 6 weeks after injection between USG and LMG groups were expressed in terms of the weighted mean difference or standard mean difference with a 95% confidence interval (CI) evaluation. For summarizing the effective rate (frequency of effective number), the risk ratio (RR) was used. We used the Cochrane Risk of bias tool to assess the methodological quality of the included RCTs in terms of sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias [11]. The significance level was defined as *P* value lower than 0.05.

Results

We identified 305 articles; seven RCTs were eligible for this review (Fig. 1), with a total of 445 adult patients [13–19]. Characteristics of the enrolled studies are described in Table 1.

Clinical outcomes

**Decreased VAS and SDQ scores at 6 weeks after injection**

Six studies assessed pain using a pain score [13–15,17–19] and two assessed SDQ score [15,18] at 6 weeks after injection. The analysis indicated a statistically significant decreased VAS and SDQ score difference between USG and LMG groups at this follow-up period in favor of USG (MD = 1.19, 95% CI (0.39, 1.98), *P* = 0.003 and MD = 5.01, 95% CI (1.82, 8.19), *P* = 0.02, respectively, Figs. 2 and 3).

![Fig. 1. Flow of participants through trial.](image-url)
Increased shoulder function scores and shoulder abduction degree at 6 weeks after injection

Four studies assessed increased shoulder function [13–15,18] and two assessed increased shoulder abduction motion range [14,16] 6 weeks after injection. This indicated a statistically significant difference between the groups, with greater improvement of shoulder function scores and shoulder abduction motion range in the USG group [SMD = 0.89, 95% CI (0.56, 1.23), \( P < 0.001 \) and MD = 32.69, 95% CI (14.82, 50.56), \( P < 0.001 \), respectively, Figs. 4 and 5].

Effective rate

Two studies compared the effective rate difference between ultrasound-guided and landmark injection groups [14,17]. More effective rate was also reported with USG group and the difference was statistically significant [risk ratio = 1.6, 95% CI (1.02, 2.50), \( P = 0.04 \), Fig. 6].

Quality of included studies

The studies reported low risk of bias in terms of sequence generation, incomplete outcome data, and selective outcome reporting. However, some studies (3/8) did not report blinding of participants and personnel and some (2/8) have high risk of other bias, including being limited by the single follow-up visit at week 6. Patients were not blinded to the injection technique and this may have resulted in some bias particularly for purely subjective assessments such as VAS. The risk of bias for shoulder function assessment in terms of blinding outcome assessment was judged to be of low risk in 7 studies. In summary, the risk of bias within the studies was medium due to potential publication bias and unknown quality (Supplementary Figs. S1 and S2).

Discussion

The purpose of this study was to assess whether there is a difference in the clinical and functional outcomes of USG versus LMG SASD bursa injections in adults with shoulder pain based on the current evidence base. A total of eight RCTs were included in our meta-analysis. The results showed that USG SASD injections were more efficient than the LMG injections. USG injections significantly decreased the VAS and SDQ scores, and increased shoulder function and shoulder abduction motion range at 6 weeks after injection.

SASD bursitis, regarded as the nonstenotic impingement of the shoulder, is a common cause of anterior shoulder pain. Painful arc syndrome develops when there is a loss of clearance or normal gliding mechanism of the walls of the subacromial bursa between the coracoacromial arc above and the humeral head below. Ultrasound has proven to be an effective tool in the diagnosis of SASD.

### Table 1

The characteristics of the enrolled studies for comparing US-guided versus landmark-guided SASD bursa injection

<table>
<thead>
<tr>
<th>First author</th>
<th>Publication year</th>
<th>Country</th>
<th>Sample size USG/LG (n)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esperanza Naredo</td>
<td>2004</td>
<td>Spain</td>
<td>21/20</td>
<td>Impingement syndrome; subacromial – subdeltoid bursitis; rotator cuff lesions</td>
</tr>
<tr>
<td>Chen M.J.L.</td>
<td>2006</td>
<td>Taiwan</td>
<td>20/20</td>
<td>Subacromial bursitis</td>
</tr>
<tr>
<td>Faik Ucuncu</td>
<td>2009</td>
<td>Turkey</td>
<td>30/30</td>
<td>Impingement syndrome; subacromial – subdeltoid bursitis; rotator cuff lesions</td>
</tr>
<tr>
<td>Zufferey P.</td>
<td>2012</td>
<td>Switzerland</td>
<td>27/29</td>
<td>Bursitis; fluid or synovitis</td>
</tr>
<tr>
<td>Dogu B.</td>
<td>2012</td>
<td>Turkey</td>
<td>23/23</td>
<td>Subacromial impingement syndrome</td>
</tr>
<tr>
<td>Lin-Fen Hsieh</td>
<td>2013</td>
<td>Taiwan</td>
<td>46/46</td>
<td>Chronic subacromial bursitis</td>
</tr>
<tr>
<td>Aamir Saeed</td>
<td>2014</td>
<td>Ireland</td>
<td>44/46</td>
<td>Subacromial impingement syndrome</td>
</tr>
</tbody>
</table>

**Fig. 2.** Forest plot of the decreased VAS scores at 6 weeks after injection.

**Fig. 3.** Forest plot of the decreased SDQ scores at 6 weeks after injection.
bursitis [20]. SASD bursitis is observed under the sonogram as a hypoechoic region correlating with an effusion between the deltoid muscle and supraspinatus. Local injection of steroid suspension into the SASD bursa may be needed if conventional therapy including physical modality or anti-inflammatory medications fails. The key point of the technique is that the needle tip should be accurately placed into the SASD bursa to achieve the ideal clinical outcomes and reduce local complications [21].

In clinical practice, injection treatment of SASD is frequently done by palpation of the acromion by the thumb, and the needle slides blindly under it in a horizontal approach [22]. However, physicians using the blind injections can never be sure about the depth of the inserted needle. Also the accuracy rate of LMG injections is poor especially in obese patients with no obvious landmark. Potential side effects of blind injection include necrotizing fasciitis, a deleterious effect on intra-articular cartilage, or tendon degeneration, which may lead to late rupture of the rotator cuff and subcutaneous atrophy [23].

The US-guided SASD bursa injection technique has become increasingly popular because of its several advantages [13]. US provides fast and less invasive real-time monitoring during needle placement with no risk of radiation exposure. A US machine is also much more affordable, acceptable to patients, and available than a machine like fluoroscopy or computed tomography/magnetic resonance scanner.

To our knowledge, this is the first meta-analysis to assess outcome of SASD bursa injections guided by ultrasound versus landmark. The recent Cochrane review reported no significant improvement in effectiveness with US-guided injections [24]. However, the limitations in that study are obvious in that there was considerable heterogeneity in the included trials, and the authors did not perform the analysis based on the injection location. So we included the study that specially involved patients for SASD bursa or subacrominal injection. Also, the biceps tendon sheath injection and glenohumeral joint injection were excluded. We required image-confirmed needle placement in SASD bursa in order to ensure precision.

The limitation of this study is the relatively small sample size in each group. The results should be interpreted with some caution due to the limited number of studies and small sample sizes available for review. More adequately powered and well-executed RCTs are required.

Conclusions

The meta-analysis in this study provides evidence that ultrasound-guided corticosteroid injections potentially offer a significantly greater clinical improvement over blind SASD injections in adults with shoulder pain. Therefore, we believe that the US-guided SASD injection technique can be a useful treatment that leads to improvements in patients with SASD bursitis.

Acknowledgments

We would like to thank all authors who shared individual patient data. No funding was received for this study.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.biopsych.2015.04.015.

References


